Cystic Fibrosis disease mechanism in adults
Cystic fibrosis (CF) is traditionally viewed as a genetic disorder primarily affecting children; however, advancements in diagnosis and treatment have led to a growing number of adults living with this condition. Understanding the disease mechanism in adults requires an appreciation of its genetic roots and how the pathophysiology evolves over a person’s lifespan.
Cystic fibrosis is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which encodes a protein functioning as a chloride channel in epithelial cells. The most common mutation, delta F508, results in misfolded CFTR proteins that are degraded before reaching the cell surface. Other mutations may produce partially functional or non-functional proteins, contributing to the broad phenotypic variability seen among patients.
In healthy individuals, CFTR channels regulate the movement of chloride and bicarbonate ions across epithelial cell membranes, maintaining the proper hydration and viscosity of mucus in organs such as the lungs, pancreas, liver, and intestines. In CF patients, defective or absent CFTR channels lead to thick, sticky mucus accumulation. This abnormal mucus impairs mucociliary clearance in the respiratory tract, creating an environment prone to persistent infections. Over time, recurrent infections and inflammation cause airway damage, bronchiectasis, and declining lung function, which are hallmarks of adult CF disease progression.
In the pancreas, thick mucus obstructs the pancreatic ducts, preventing enzymes from reaching the intestines and resulting in malabsorption of nutrients. This can lead to nutritional deficiencies, poor growth, and weight loss. Additionally, the impaired bicarbonate secretion in the gastrointestinal tract exacerbates mucus dehydration, worsening blockages and contributing to gastrointestinal symptoms such as constipation or meconium ileus in some cases.
In adults, the disease mechanism often becomes more complex due to cumulative lung damage, chronic infections (notably with Pseudomonas aeruginosa and other bacteria), and the development of comorbidities such as CF-related diabetes. The persistent inflammation caused by infection and immune response damages the airway epithelium, leading to structural changes and progressive decline in lung function. This cycle of infection, inflammation, and tissue remodeling perpetuates respiratory deterioration in adulthood.
Moreover, advances in CF care, including the use of CFTR modulators, have transformed the disease’s trajectory. These drugs target specific CFTR mutations, improving protein function and mitigating some of the underlying defect. For adults, this means a potential slowdown in disease progression, though the extent varies based on mutation type and disease severity at diagnosis.
The complexity of CF in adults underscores the importance of a multidisciplinary approach to management. Addressing the fundamental defect at the molecular level, managing infections, ensuring adequate nutrition, and monitoring lung function collectively aim to improve quality of life and extend survival. As research continues, understanding the intricate disease mechanisms at play in adulthood will be vital in developing more targeted and effective therapies.
